A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).

The primary objectives of this study are:

- To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily
(od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial
infarction, stroke, or cardiovascular death in subjects with coronary artery disease
(CAD) or peripheral artery disease (PAD);

- To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the
risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects
with CAD or PAD.